Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?

  title={Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?},
  author={Ryan W. Chapin and Tiffany Lee and Christopher M McCoy and Carolyn D. Alonso and Monica V. Mahoney},
  journal={Annals of Pharmacotherapy},
  pages={804 - 810}
Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of bezlotoxumab (BEZ), a novel monoclonal antibody against Clostridium difficile toxin B. Data Sources: A PubMed search was conducted for data between 1946 and April 2017 using MeSH terms bezlotoxumab, MK-6072, or MDX-1388 alone and the terms Clostridium difficile combined with monoclonal antibody or antitoxin. Study Selection and Data Extraction: The literature search was limited to English-language… 

Tables from this paper

Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
Overall, bezlotoxumab demonstrated a 40% relative reduction rate (absolute rate reduction of ~10%) and a number needed to treat of 10 patients with a favorable safety profile, and special populations, including the elderly, immunocompromised, and patients with end-stage renal disease were evaluated in post hoc analyses with a similarly favorable reduction in rCDI.
Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies
Overall, bezlotoxumab has proved efficacious in reducing the burden of rCDI, thereby providing clinicians with an important novel strategy to achieve sustained cure, and experiences outside randomized controlled trials (RCTs) remain scant.
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
A combination of two HuMabs could potentially offer an advantage for a yet to emerge C. difficile strain, which is a steady threat for patients at high risk of CDI, and future research will be needed to assess HuMab combination as a therapeutic strategy in clinical and microbiological cure ofCDI.
Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection
Bezlotoxumab may be a good therapeutic option for severe C. difficile infection rather than mild cases and the effectiveness and safety of bezlotOxumab for the prevention of rCDI were demonstrated.
Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
Clostridium difficile infection (CDI) is the most common health care-acquired infection associated with high hospital expenditures. The incidence of subsequent recurrent CDI increases with prior
Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
Oral vancomycin prophylaxis for the prevention of Clostridium difficile infection: A systematic review and meta-analysis
The results suggest that OVP might decrease CDI rates in at-risk populations, although this conclusion should be interpreted with caution.
Update of treatment algorithms for Clostridium difficile infection.
  • R. Ooijevaar, Y. V. van Beurden, E. Kuijper
  • Medicine, Biology
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2018
Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance?
The number of new antibiotics and their indications are not keeping up with resistance and the needs of the patients.
Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of Clostridium difficile Recurrence
Use of OVP in subjects with a history ofCDI up to 12 months prior to subsequent antibiotic exposure appears to reduce the risk of CDI recurrence for up to 10 months, compared to 6.3% in subjects who did not receive prophylaxis.


Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
Among participants receiving antibiotic treatment for primary or recurrent C. difficile infection, bezlotoxumab was associated with a substantially lower rate of recurrent infection than placebo and had a safety profile similar to that of placebo.
Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab
It is shown that the antitoxin antibodies are protective in multiple murine models of CDI, including systemic and local (gut) toxin challenge models, as well as primary and recurrent models of infection in mice, providing a mechanistic basis for the prevention of recurrent disease observed in CDI patients in clinical trials.
Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection
This retrospective, propensity-matched cohort study evaluated patients treated for CDI, defined as a positive laboratory test result for the presence of C difficile toxins or toxin genes in a stool sample, in the US Department of Veterans Affairs health care system from January 1, 2005, through December 31, 2012 to evaluate the risk of recurrence and all-cause 30-day mortality.
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.
The findings suggest that metronidazole and vancomycin are equally effective for the treatment of mild CDAD, but vancomYcin is superior for treating patients with severe CDAD.
Fidaxomicin versus vancomycin for Clostridium difficile infection.
Fidaxomicin was associated with a significantly lower rate of recurrence of C. difficile infection associated with non–North American Pulsed Field type 1 strains and the adverse-event profile was similar for the two therapies.
Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.
  • Swati B. Gupta, Vinay Mehta, T. Mast
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2016
A predictor of recurrence was age ≥65 years, and an antibody-mediated immune response to toxin B appears to be protective against rCDI, demonstrating the importance of clinical as well as immunological risk factors in rCDi.
Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections
Oral vancomycin appears as an effective strategy for decreasing the risk of further CDI recurrence in patients with a history of recurrent CDI who are re-exposed to antibiotics.